LanroNET - A Non-Interventional Prospective Study to Assess the Resource Utilisation and Cost of Lanreotide Autogel 120 mg in the Population of Polish Patients with Symptomatic Neuroendocrine Tumours

Introduction: The primary objective of the LanroNET study was to evaluate the resource utilisation and cost of symptomatic treatment of patients with neuroendocrine tumours (NET) using lanreotide autogel 120 mg. Material and methods: LanroNET was a multicentre, non-interventional, prospective study conducted at 12 clinical centres in Poland. Eligible patients were adults with symptomatic NET treated with lanreotide autoge1120 mg at least three months before enrolment. During 24-months of observation of real clinical practice, data on medical resource utilisation and the therapy course of patients with symptomatic NET were collected. Results: Fifty-four patients with symptomatic NET were enrolled. The median time of lanreotide exposure was 1.7 years (range: 0.0-2.2). Thirty-three patients completed the study; the most frequent known cause of discontinuation (8/16) was disease progression. The mean cost of consumed resources without the cost of pharmacotherapy was estimated at PLN 26,307/EUR 6030.35 per year. During the study, the mean (SD) interval between injections was 31.7 days (6.7). At the end of observation - after 24 months of follow-up, seven patients were on a 42-day regimen. The average real-world cost of lanreotide autoge1120 mg was PLN 4216.30/EUR 966.49 per patient/28 days from the public payer and patient perspective and was lower by PLN 554.14/EUR 127.02 than the cost for the standard 28-day dosing interval. Conclusions: LanroNET is the first two-year observational study of patients with symptomatic NET evaluating the cost of every-day clinical practice and lanreotide autogel treatment in Poland.